<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Hartvig Hardy | Activity</title>
	<link>https://www.catswannabecats.com/members/commabath15/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/commabath15/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Hartvig Hardy.</description>
	<lastBuildDate>Sat, 27 Jun 2026 07:28:19 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">e10f9bdcd474bc7de06a75b53222e3a9</guid>
				<title>Hartvig Hardy posted an update: TRV130 (oliceridine), a G protein-biased ligand for [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/24551/</link>
				<pubDate>Sun, 08 Jun 2025 12:57:28 -0400</pubDate>

									<content:encoded><![CDATA[<p>TRV130 (oliceridine), a G protein-biased ligand for μ-opioid receptor, has recently been synthesized. It is considered to have strong antinociceptive effects and only minor adverse effects. However, whether or not oliceridine actually exhibits an ideal pharmacological profile as an analgesic has not yet been fully clarified in animal studies.&hellip;<span class="activity-read-more" id="activity-read-more-24551"><a href="https://www.catswannabecats.com/activity/p/24551/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">60cfdd32a49a159ba7285935c20184a4</guid>
				<title>Hartvig Hardy posted an update: Patients exposed to chronic sustained hypoxia frequently [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/22124/</link>
				<pubDate>Sat, 07 Jun 2025 08:11:20 -0400</pubDate>

									<content:encoded><![CDATA[<p>Patients exposed to chronic sustained hypoxia frequently develop cardiovascular disease risk factors to ultimately succumb to adverse cardiovascular events. In this context, the present study intends to assess the role of cilnidipine (Cil), a unique calcium channel blocker that blocks both L-type and N-type calcium channels, on cardiovascular&hellip;<span class="activity-read-more" id="activity-read-more-22124"><a href="https://www.catswannabecats.com/activity/p/22124/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6288d8a9f8d3f05df363ed2ccaa75aca</guid>
				<title>Hartvig Hardy posted an update: Chemolithoautotrophic nitrite-oxidizing bacteria (NOB) are [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/7514/</link>
				<pubDate>Sat, 31 May 2025 19:26:43 -0400</pubDate>

									<content:encoded><![CDATA[<p>Chemolithoautotrophic nitrite-oxidizing bacteria (NOB) are key players in global nitrogen and carbon cycling. Members of the phylum Nitrospinae are the most abundant, known NOB in the oceans. To date, only two closely affiliated Nitrospinae species have been isolated, which are only distantly related to the environmentally abundant uncultured&hellip;<span class="activity-read-more" id="activity-read-more-7514"><a href="https://www.catswannabecats.com/activity/p/7514/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cbf69a31ba6ebb586cda8590f5a9b114</guid>
				<title>Hartvig Hardy became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/7415/</link>
				<pubDate>Sat, 31 May 2025 19:12:46 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>